A newer IDH1 inhibitor FDA-approved in 2022, olutasidenib, has shown longer durations of complete remission in a phase I/II study (NCT02719574) with IDH1 mutant AML patients compared to ivosidenib, although it has not yet been investigated in a head-to-head trial [94]. This evidence concerns the gene IDH1 and acute myeloid leukemia.